Newborn Screening Market

Market Overview:

The global newborn screening market size reached US$ 956 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,467 Million by 2028, exhibiting a growth rate (CAGR) of 7.5% during 2023-2028.

Newborn screening is a public healthcare initiative focusing on infant screening, parental education, appropriate follow-up, diagnostic testing, disease management, and continued evaluation. It targets diseases that can cause significant morbidity, mortality, and intellectual disability (ID). Some of these diseases included in the newborn screening tests are galactosemia, phenylketonuria (PKU), homocystinuria, hearing loss, sickle cell disease (SCD), biotinidase deficiency, maple syrup urine, congenital adrenal hyperplasia, and medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Nowadays, public healthcare organizations across the globe are adopting new testing techniques, such as tandem mass spectrometry (MS/MS), to detect disorders associated with protein and fatty acid metabolism using blood samples.

Newborn Screening Market Trends:

The rising prevalence of congenital conditions among infants, along with increasing concerns among parents about the health of children, represents one of the significant factors influencing the market. Newborn screening relies on a specific set of laboratory evaluations and point-of-care examinations for early detection, diagnosis, and intervention of disorders. These disorders are genetic, metabolic, blood, or hormone-related, which are not immediately apparent after delivery and require practical intervention. This, coupled with the rising awareness about early diagnosis and improving diagnostic modalities, is propelling the growth of the market. Moreover, with the development of robust immunoassays and molecular diagnostics, disorders like primary hypothyroidism, cystic fibrosis (CF), and congenital toxoplasmosis are being targeted in several newborn screening tests. Apart from this, governing agencies of numerous countries are planning to mandate newborn screening programs due to increasing child morbidity and mortality, which is also contributing to market growth. Furthermore, the leading players are engaged in building strategic partnerships to ensure product sustainability, which is anticipated to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global newborn screening market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, technology and test type.

Breakup by Product:

• Instruments
• Reagents
   

Breakup by Technology:

• Tandem Mass Spectrometry
• Pulse Oximetry
• Enzyme Based Assay
• DNA Assay
• Electrophoresis
• Others
   

Breakup by Test Type:

• Dry Blood Spot Test
• CCHD
• Hearing Screen
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Baebies Inc., Bio-RAD Laboratories Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, Masimo Corporation, Medtronic plc, Natus Medical Incorporated, Perkinelmer Inc., RECIPE Chemicals + Instruments GmbH, Thermo Fisher Scientific Inc., Trivitron Healthcare and Waters Corporation.

Report Coverage: